Parliament watchdog wants sluggish value-based pricing discussion clarified by March
This article was originally published in Scrip
Executive Summary
The UK Parliament’s Health Select Committee which monitors England's Department of Health, is calling for the department to work out plans for value-based pricing by the end of March. The lack of progress and clarity on the new arrangements so far, it said, is “unacceptable”.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.